Belite Bio
BLTE
75 hedge funds and large institutions have $1.42B invested in Belite Bio in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 21 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 15
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
23% more capital invested
Capital invested by funds: $1.15B → $1.42B (+$269M)
9% more funds holding
Funds holding: 69 → 75 (+6)
4% more ownership
Funds ownership: 19.17% → 23.17% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$187M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$108M |
| 3 |
Holocene Advisors
New York
|
+$69M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.4M |
| 5 |
Morgan Stanley
New York
|
+$29.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$69.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$45.5M |
| 3 |
PA
Perceptive Advisors
New York
|
-$44.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$30.8M |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$9.6M |
BLTE Hedge Fund Activity: Q1 2026 in Review
75 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q1 2026, worth a combined $1.42B — up 23% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new BLTE positions and 21 closed out — a net gain of 7 holders — while 26 added to existing stakes and 15 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $187M. The largest seller was RA Capital Management, exiting entirely with an estimated $69.2M sold.
- 75 institutional investors held Belite Bio (BLTE) as of Q1 2026, up from 69 in Q4 2025.
- Funds reported $1.42B of Belite Bio stock for Q1 2026, up 23% quarter-over-quarter.
- 28 funds opened new Belite Bio positions in Q1 2026 and 21 closed out, a net change of +7 holders.
- The largest Belite Bio buyer in Q1 2026 was Paradigm Biocapital Advisors, an estimated $187M added.
- The largest Belite Bio seller in Q1 2026 was RA Capital Management, an estimated $69.2M sold.
Based on aggregated 13F filings for Q1 2026.